BIO and the Delaware BioScience Association commend Delaware State Senate for introducing legislation designed to address regulatory issues related to the interchangeability of biological medicines. Biosimilars are not generics, and even slight changes to biologic drug can change its properties entirely. Senate Bill 118 seeks to properly preserve physician-patient relationship, protect patient access to accurate prescription information, and promote competitive market for biologic ...This story is related to the following:Trade Associations